Innovation in

Vybion is the leading developer of Intrabodies for neurodegenerative diseases, leveraging the safety and effectiveness of antibody technologies to address unmet medical needs. Vybion Intrabodies are scFv fragments that target and change the fate of intracellular events like the protein aggregation, gene dysregulation and turnover of toxic protein fragments as a disease modifying approach to therapeutics.


December 3rd, 2018
Vybion Receives Orphan Drug Designation for INT41 in Huntington's Disease

April 3rd, 2018
Patent Issues for Novel Huntington's and Alzheimer's Disease Gene Therapy...

December 15th, 2017
Vybion gives invited presentation at annual virtual conference Emerging Medical Technologies Spotlight...

November 16th, 2017
Vybion gives an invited talk at the SNO-SCIDOT joint conference...

February 20, 2017
Intrabody Delivered with Adeno-Associated Virus Blocking Gene Dysregulation Offers Hope in Treating Huntington's Disease...

Huntington's Disease

The first therapeutic to emerge from PharmCode is INT41, an intrabody currently delivered with AAV for the treatment of Huntington's disease. INT41 is a disease modifying drug that blocks gene dysregulation and the action of toxic Huntingtin mutant protein fragments in the nucleus.